Literature DB >> 3510795

Effects of combination therapy with captopril and nifedipine in severe or resistant hypertension.

W B White, J J Viadero, T J Lane, S Podesla.   

Abstract

To assess the effect of potent vasodilator therapy in patients with severe or resistant hypertension, 10 patients underwent therapy with captopril and nifedipine alone and in combination. Blood pressure (BP), heart rate, and blood chemistry values were monitored for 4 weeks during captopril monotherapy and after 8 weeks during combination therapy with captopril and nifedipine. Compared with baseline, the BP decreased during captopril monotherapy (180 +/- 11/98 +/- 7 vs. 209 +/- 16/118 +/- 12 mm Hg; P less than 0.005). After the addition of nifedipine, the BP was further reduced (148 +/- 23/85 +/- 16 mm Hg), but there was no change in heart rate. In three patients not achieving the diastolic BP goal during combination therapy with dosing every 8 hours, automatic 24-hour ambulatory BP monitoring demonstrated lack of antihypertensive control for only the last 2 to 3 hours of the dosing interval. These data demonstrate that combination therapy with captopril and nifedipine is effective in patients with severe hypertension, but frequent dosing intervals are necessary for adequate antihypertensive control.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3510795     DOI: 10.1038/clpt.1986.8

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  Hypertension: antihypertensive class matters for combination therapy.

Authors:  William B White
Journal:  Nat Rev Cardiol       Date:  2010-06       Impact factor: 32.419

Review 2.  Nifedipine interactions in hypertensive patients.

Authors:  A Salvetti; A Magagna; B Abdel-Haq; M Lenzi; R Giovannetti
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

3.  Long-Term Tolerability and Efficacy of Single-Pill Combinations of Telmisartan 40-80 mg Plus Amlodipine 5 or 10 mg in Patients Whose Blood Pressure Was Not Initially Controlled by Amlodipine 5-10 mg: Open-Label, Long-Term Follow-Ups of the TEAMSTA-5 and TEAMSTA-10 Studies.

Authors:  Steen Neldam; Colin Edwards; Margreet Lang; Russell Jones
Journal:  Curr Ther Res Clin Exp       Date:  2012-02

Review 4.  Pharmacologic treatment of chronic pediatric hypertension.

Authors:  Renee F Robinson; Milap C Nahata; Donald L Batisky; John D Mahan
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 5.  Angiotensin converting enzyme inhibitors and moderate hypertension.

Authors:  D McAreavey; J I Robertson
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 6.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

Review 7.  Pharmacokinetics as an aid to optimising compliance with medications.

Authors:  P Rudd; L Lenert
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

Review 8.  [Have angiotensin-converting enzyme inhibitors improved therapy of hypertension?].

Authors:  K H Rahn
Journal:  Klin Wochenschr       Date:  1988-09-15

Review 9.  Angiotensin converting enzyme inhibitors in the treatment of hypertension: efficacy, metabolic effects and side effects.

Authors:  M H Weinberger
Journal:  Cardiovasc Drugs Ther       Date:  1987       Impact factor: 3.727

10.  Enalapril in essential hypertension: the comparative effects of additional placebo, nicardipine and chlorthalidone.

Authors:  R Donnelly; H L Elliott; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.